Dapagliflozin is a medication being studied for its potential to prevent heart damage in breast cancer patients who are receiving a specific type of chemotherapy known as anthracycline-based chemotherapy. This medication is typically used to treat diabetes by helping the kidneys remove glucose from the bloodstream. In this trial, researchers are investigating whether it can also protect the heart from the harmful effects of chemotherapy.

Invasive Breast Cancer – This type of cancer begins in the breast tissue and has the potential to spread to surrounding tissues or other parts of the body. It is categorized into stages I to III, with each stage indicating the extent of cancer spread. Stage I is the earliest, where cancer is confined to the breast, while stage III indicates more extensive spread to nearby lymph nodes or tissues. The progression of invasive breast cancer can vary, with some cases growing slowly and others more rapidly. Treatment plans often depend on the stage and specific characteristics of the cancer. Regular monitoring and follow-up are crucial to manage the disease effectively.

Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD) – This condition occurs as a side effect of certain cancer treatments, particularly those involving anthracyclines. It involves damage to the heart muscle, leading to impaired heart function. Symptoms may include heart failure signs, such as shortness of breath or fatigue, but it can also be asymptomatic with changes detected through imaging or biomarker tests. The dysfunction can manifest as a decrease in the heart’s ability to pump blood effectively, often measured by a reduction in left ventricular ejection fraction. Monitoring heart function during and after cancer treatment is essential to detect and manage CTRCD. The condition’s progression can vary, and early detection is key to preventing further cardiac complications.